When it comes to new brain anatomy, clearance pathways seem to be the gift that keeps on giving. In a preprint posted September 27 on bioRxiv, scientists led by David Attwell at University College ...
How much do blood-based biomarkers help in diagnosing Alzheimer’s disease? Quite a lot, according to scientists led by Albert Puig Pijoan and Marc Suárez-Calvet at the Hospital del Mar in Barcelona, ...
Another tau-lowering drug has shown it can hit its target in a Phase 1 trial. Arrowhead Pharmaceuticals, based in Pasadena, California, reported October 14 that its brain shuttle, tau-directed siRNA, ...
Two groups of scientists have found that the same protein can have opposing effects on α-synuclein pathology. Microglia eliminate α-synuclein from neurons by “trogocytosis.” Silencing the glycoprotein ...
In the latest development on diagnostic methods for Alzheimer’s disease going mainstream, the U.S. Food and Drug Administration approved clinical use of Lantheus’ tau PET tracer florquinitau, aka ...
Also the 24th Alzheimer's Disease and Related Disorders Annual convention of the Dementia Society of the Philippines ...
Applications may request budgets of up to $1.5 million in direct costs per year; however, most awards are expected to be between $500,000–$900,000 in direct costs annually. Applications may request up ...
Nutrient Formulation Appears to Grease Memory Function Door Slams on RAGE Whence and Where To: History and Future of AD Therapy Trials Clinical Trials: Making “Protocols From Hell” Less Burdensome EEG ...
News Bad Origami: Misfolded SOD1 in Living Color 30 Jan 2009 Secretion of SOD1 Mutant Proteins Tied to ALS 23 Dec 2005 Motoneuron Mitochondria: Preferred Destination For Mutant SOD1 12 Jul 2004 The ...
Elizabeth Barbehenn, Ph.D. Public Citizen' Health Research Group Contact Information Elizabeth Barbehenn, Ph.D. United States ...
FUS (Fused in Sarcoma) is a member of a family of RNA-binding proteins with roles in transcription, RNA processing, RNA transport, and translation. Mutations in FUS, many of which are clustered near ...
Clinicians have started using blood tests of p-tau217, a marker of amyloid plaques, to help diagnose AD in routine patient care, not just research studies. Alas, at AD/PD 2026, held March 17-21 in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results